TLR9: CpG-conjugated 18 amino acid lytic peptides to treat TLR9+ MDS

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Charlie Shaw, PhD
Associate Director, Patents and Licensing
813.745.6639
Charlie.Shaw@moffitt.org

16MB039N